Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Deal Origination Executive Search For Sales Teams Corporate Development For Founders For Agencies For Investors Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Start Free
Apollo Therapeutics logo — A transformative idea for transformative medicines

Apollo Therapeutics

A transformative idea for transformative medicines

Founded 2016 59 employees Series C Total: $313.50M Biopharma, Biotechnology +2

General Information

Company Name Apollo Therapeutics
Founded Year 2016
Founders / Decision Makers
Dr. Richard Mason — CEO Dr. Sanjay Aggarwal — CMO
Employees 59
Industries Biopharma, Biotechnology, Health Care +1
Funding Stage Series C
Social

Get notified when Apollo Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Apollo Therapeutics

Apollo Therapeutics is a burgeoning biopharmaceutical company that is rapidly advancing a robust pipeline of potentially transformative therapeutic programs based on breakthrough discoveries. Founded in 2016, the company's innovative model was created in late 2015 by three world-leading universities - Cambridge, Imperial College London, and University College London - in partnership with AstraZeneca, GlaxoSmithKline, and Johnson & Johnson Innovation. The company's vision is encapsulated in their slogan, "A transformative idea for transformative medicines." With a vision to bring new treatments to the market, Apollo Therapeutics is focusing on scaling a robust and potentially transformative pipeline, with over 15 therapeutic programs in development today across oncology, major inflammatory disorders, and rare diseases. Their approach revolves around deep relationships with world-leading universities and scientists, enabling them to identify programs with strong biological hypotheses and potential to become meaningful new treatment options. They have a centralized team of drug development 'architects' and subject matter experts who rigorously evaluate therapeutic programs in an objective, data-driven manner - prioritizing critical experiments to de-risk programs early, hence ensuring capital efficiency. The company's growth is fueled by a $33.50M Series C investment at 02 January 2024, led by Patient Square Capital, Rock Springs Capital, and M&G plc. This financing has enabled them to expand their operations in Cambridge, UK and Boston, USA. As they move forward, Apollo Therapeutics aims to build on their existing collaborations, foster new relationships with additional top academics globally, and in-license drug candidates from new partners. For more information about Apollo Therapeutics, visit their website at www.apollotherapeutics.com

Taxonomy: biopharmaceutical, therapeutic programs, drug development, pipeline, oncology, inflammatory disorders, rare disease, university partnerships, accelerated drug development, capital efficiency, clinical development, venture funding, global collaborations, biotech innovation, expanding operations

Funding Rounds & Investors (4)

View All
Funding Stage Amount Investors Lead Investors Date
Series C $33.50M 3
Patient Square Capital Rock Springs Capital M&G plc
02 Jan 2024
Series C £180.00M 3
Patient Square Capital Rock Springs Capital M&G plc
06 Sep 2023
Series B £100.00M 4
Patient Square Capital Rock Springs Capital UCL Tech Fund Reimagined Ventures
17 Jun 2021
Seed Round Unknown - 01 Jan 2017

Apollo Therapeutics Alternatives & Competitors

Apollo Therapeutics vs
Mission Therapeutics
Mission Therapeutics United Kingdom

Mission Therapeutics is a private, drug discovery and development company focused on selectively tar...

Grant
34 employees
Biotechnology, Health Care
Compare Apollo Therapeutics vs Mission Therapeutics
Apollo Therapeutics vs
OCEAN BIOMEDICAL
OCEAN BIOMEDICAL United States

Empowering great medical science.

Post Ipo Debt
12 employees
Biotechnology, Health Care
Compare Apollo Therapeutics vs OCEAN BIOMEDICAL

FAQ About Apollo Therapeutics

A transformative idea for transformative medicines
Apollo Therapeutics was founded in 2016.
Apollo Therapeutics operates in the following industries: Biopharma, Biotechnology, Health Care, Health and Wellness.
Apollo Therapeutics has approximately 59 employees.
Apollo Therapeutics has completed 4 funding rounds, raising a total of $313.50M. The latest funding stage is Series C.
Top alternatives and competitors to Apollo Therapeutics include Mission Therapeutics, OCEAN BIOMEDICAL. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
Apollo Therapeutics and Mission Therapeutics are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors Apollo Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

Start Tracking — Free

One analytics cookie (Google Analytics). Cookie Policy